DAREHIGH SIGNALFINANCIAL10-K

DARE experienced a dramatic deterioration in operating performance with revenue plummeting 72% while burning through cash, despite improved balance sheet position from apparent equity financing.

The company's core business appears to be in serious distress, with revenue collapsing from $10M to $2.8M and operating cash flow swinging from positive $5.4M to negative $9.9M. While the company has strengthened its balance sheet through what appears to be significant equity financing (outstanding shares increased 65% and stockholders' equity turned positive), the underlying operational performance suggests fundamental business challenges that investors should view as a major red flag.

Comparing 2026-03-26 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

DARE's financial picture shows a tale of two stories - a severely deteriorating operating business offset by successful capital raising. Revenue collapsed 72% while the company burned $9.9M in operating cash flow compared to generating $5.4M previously, indicating serious operational challenges. However, the balance sheet strengthened significantly with cash increasing 57% to $24.7M and stockholders' equity turning positive, suggesting the company completed a substantial equity raise (reflected in the 65% increase in outstanding shares) that provides near-term liquidity but at significant dilution to existing shareholders.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-283.3%
$5.4M-$9.9M

Operating cash flow fell 283.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
-230.6%
-$4.1M-$13.4M

Net income declined 230.6% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
+147.3%
-$6.0M$2.8M

Equity base grew 147.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Interest Expense
P&L
-85.6%
$2.2M$323K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
-71.9%
$10.0M$2.8M

Revenue declined 71.9% — significant demand weakness or market share loss warrants investigation.

R&D Expense
P&L
-61.1%
$14.2M$5.5M

R&D spending cut 61.1% — could signal cost discipline or concerning reduction in innovation investment.

Cash & Equivalents
Balance Sheet
+57.4%
$15.7M$24.7M

Cash position surged 57.4% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+46.9%
$22.1M$32.5M

Asset base grew 46.9% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+46.7%
$18.4M$27.1M

Current assets grew 46.7% — improving short-term liquidity or inventory/receivables build.

Operating Income
P&L
+42.2%
-$23.5M-$13.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-31
ADDED
As of March 25, 2026, there were 14,559,502 shares of the registrant s common stock, par value $0.0001 per share, outstanding.
Overview We are a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions.
Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research.
From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, we re working to close critical gaps in care using science that serves her needs.
For decades, women have been told to wait it out or live with it, while innovations that could improve their quality of life languish in the regulatory or funding pipeline.
+7 more — sign up free →
REMOVED
As of March 28, 2025, there were 8,850,386 shares of the registrant s common stock, par value $0.0001 per share, outstanding.
Overview We are a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority.
We exist to accelerate innovation in women s health and we believe that innovation does not have to start from scratch.
With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting, but access to real, evidence-based solutions still lags behind.
We continuously hear from healthcare providers, researchers, and women themselves about the urgent need for access to evidence-based treatment options.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →